These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31914797)

  • 41. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
    Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
    J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
    Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation.
    Tam LS; Tomlinson B; Chu TT; Li M; Leung YY; Kwok LW; Li TK; Yu T; Zhu YE; Wong KC; Kun EW; Li EK
    Rheumatology (Oxford); 2008 May; 47(5):718-23. PubMed ID: 18400833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
    Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
    J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Social distribution of diabetes, hypertension and related risk factors in Barbados: a cross-sectional study.
    Howitt C; Hambleton IR; Rose AM; Hennis A; Samuels TA; George KS; Unwin N
    BMJ Open; 2015 Dec; 5(12):e008869. PubMed ID: 26685026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.
    Mundal L; Veierød MB; Halvorsen T; Holven KB; Ose L; Iversen PO; Tell GS; Leren TP; Retterstøl K
    Eur J Prev Cardiol; 2016 Dec; 23(18):1962-1969. PubMed ID: 27558979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study.
    Burchfiel CM; Hamman RF; Marshall JA; Baxter J; Kahn LB; Amirani JJ
    Am J Epidemiol; 1990 Jan; 131(1):57-70. PubMed ID: 2293753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study.
    Divisón-Garrote JA; Prieto-Díaz MÁ; Alonso-Moreno FJ; Velilla-Zancada SM; Escobar-Cervantes C; Llisterri-Caro JL; Cinza-Sanjurjo S; Rodríguez-Roca GC; Polo-García J; Pallarés-Carratalá V; ; ; ;
    Semergen; 2020 Mar; 46(2):107-114. PubMed ID: 31395479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Iyen B; Qureshi N; Kai J; Akyea RK; Leonardi-Bee J; Roderick P; Humphries SE; Weng S
    Atherosclerosis; 2019 Aug; 287():8-15. PubMed ID: 31181417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors.
    Alonso R; Mata N; Castillo S; Fuentes F; Saenz P; Muñiz O; Galiana J; Figueras R; Diaz JL; Gomez-Enterría P; Mauri M; Piedecausa M; Irigoyen L; Aguado R; Mata P;
    Atherosclerosis; 2008 Oct; 200(2):315-21. PubMed ID: 18243212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
    Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.
    Pećin I; Hartgers ML; Hovingh GK; Dent R; Reiner Ž
    Eur J Prev Cardiol; 2017 Sep; 24(13):1383-1401. PubMed ID: 28644091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.
    Jansen AC; van Aalst-Cohen ES; Tanck MW; Trip MD; Lansberg PJ; Liem AH; van Lennep HW; Sijbrands EJ; Kastelein JJ
    J Intern Med; 2004 Dec; 256(6):482-90. PubMed ID: 15554949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum magnesium is inversely associated with coronary artery calcification in the Genetics of Atherosclerotic Disease (GEA) study.
    Posadas-Sánchez R; Posadas-Romero C; Cardoso-Saldaña G; Vargas-Alarcón G; Villarreal-Molina MT; Pérez-Hernández N; Rodríguez-Pérez JM; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG; Torres-Tamayo M
    Nutr J; 2016 Mar; 15():22. PubMed ID: 26931571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Trends in prevalence of risk factors and global cardiovascular risk in general population of albacete, Spain (1992-94 a 2004-06)].
    Divisón Garrote JA; Massó Orozco J; Carrión Valero L; López Abril J; Carbayo Herencia JA; Artigao Rodenas LM; Gil Guillén V;
    Rev Esp Salud Publica; 2011 Jun; 85(3):275-84. PubMed ID: 21892552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.